Amid high-profile CAR-T safety probe, FDA’s Peter Marks offers first glimpse at data under review
Fierce Pharma
JANUARY 25, 2024
Three months after launching an investigation into the risk of patients developing secondary T-cell cancers after receiving a CAR-T drug, the FDA has shared more information on the cases it has see | Three months after launching an investigation into the risk of secondary T-cell cancers after treatment with a CAR-T medicine, the FDA has shared more information on the cases that it has seen.
Let's personalize your content